Purpose of the clinical trial platform evaluation checklist
This checklist is designed to support structured evaluation of clinical trial platforms during vendor selection, system modernization, or architecture review.
Rather than comparing individual features, the checklist focuses on system characteristics that directly affect:
- Data integrity
- Compliance readiness
- Operational efficiency
- Long-term scalability
- Inspection readiness
Clinical trial platforms may appear functionally similar while differing significantly in architecture, data governance, and operational complexity.
For sponsors and CROs, many technology-related challenges emerge only after:
- Trials scale
- Regulatory inspections occur
- Global operations expand
- System integrations increase
This checklist is intended to surface those considerations early, when architectural decisions can still be evaluated objectively.
Learn more about unified clinical trial platformsClinical trial platform evaluation checklist summary
Platform architecture
How the platform is structurally designed
Key questions
- Single shared database or multiple databases?
- Are subjects, sites, visits, and documents defined once or duplicated?
- How are rules and controls enforced across functions?
Why it matters
Architecture determines whether data consistency is enforced by design or depends on synchronization and reconciliation.
Data flow
How data moves across clinical and operational workflows
Key questions
- Is data available in real time or through batch/ETL processes?
- How are updates propagated across functions?
Why it matters
Delayed or asynchronous data flow introduces operational lag and increases reliance on manual coordination.
Data reconciliation
The need to align data across systems
Key questions
- Is data reconciliation required between clinical, operational, and document systems?
- How are discrepancies identified and resolved?
Why it matters
Reconciliation increases workload, introduces delay, and raises the risk of inconsistency.
Compliance readiness
How the platform supports regulatory expectations
Key questions
- How are audit trails generated and reviewed?
- Are 21 CFR Part 11 controls applied consistently?
- How are GDPR, ICH-GCP, and ALCOA+ principles supported?
Why it matters
Regulators assess whether systems can demonstrate traceability and data integrity without cross-system reconstruction.
Audit trails
Scope and continuity of auditability
Key questions
- Is there one unified audit trail or multiple system-specific logs?
- How is historical activity preserved during changes?
Why it matters
Fragmented audit trails increase inspection effort and the risk of incomplete lineage.
Validation approach
How validation is established and maintained
Key questions
- Is validation performed separately per system or across a unified platform?
- How is change impact assessed?
Why it matters
Validation complexity increases with the number of independent systems and interfaces.
Vendor transparency
Clarity and substance of vendor explanations
Key questions
- How many databases support the platform?
- Where do authoritative records reside?
- How are migrations and upgrades handled?
Why it matters
Architecture-level answers indicate maturity and reveal long-term operational implications.
Long-term scalability
Ability to support future studies and portfolios
Key questions
- How does the platform scale across studies, regions, and functions?
- What changes as operational complexity increases?
Why it matters
Early architectural choices determine whether platforms remain manageable as trial portfolios grow.
Key clinical trial platform evaluation criteria
When assessing clinical trial platforms, buyers should examine:
- How systems are structured
- How data is governed
- How controls are applied across functions
- How operational complexity is managed over time
Platforms may support similar workflows on the surface, but their architectural foundations determine how reliably they scale, integrate, and support regulatory oversight.
Architecture determines whether operational complexity is coordinated through integrations or reduced by design.
Platform architecture (single database vs multi-database)
System architecture determines how data is created, shared, and governed across clinical, operational, and oversight workflows.
Evaluation considerations
- Does the platform operate on a single shared database, or are functions supported by separate databases connected through interfaces?
- Are core entities (such as subjects, sites, visits, users, and documents) defined once or duplicated across modules?
- How are validation rules, access controls, and data relationships enforced across functions?
Why this matters
In multi-database architectures, consistency depends on synchronization and reconciliation. In single-database architectures, consistency is enforced by design. This distinction affects oversight, change management, and inspection readiness throughout the trial lifecycle.
Data flow and data reconciliation
How data moves between systems directly affects trial speed, operational workload, data reliability, and oversight quality.
Evaluation considerations
- Is data available in real time across functions, or does it move through batch transfers or ETL processes?
- Is data reconciliation required between clinical, operational, and document systems?
- How are discrepancies detected, resolved, and documented?
Why this matters
Data reconciliation is structurally required when systems maintain separate databases. Reconciliation activities introduce delay, manual effort, and operational risk — particularly as studies increase in size, complexity, and geographic scope.
Compliance readiness and auditability
Compliance readiness reflects how well a platform supports regulatory expectations through system behavior, not just procedural controls.
Evaluation considerations
- How are audit trails generated, maintained, and reviewed across functions?
- Are controls for electronic records and signatures applied consistently?
- How does the platform support requirements related to 21 CFR Part 11, GDPR, ICH-GCP, and ALCOA+ principles?
Why this matters
Inspection readiness becomes more complex when auditability depends on multiple systems of record. Platforms that rely on cross-system reconstruction to explain data lineage increase inspection effort and operational risk.
Long-term scalability
The ability to support future studies and growing portfolios without increasing operational complexity or governance burden.
Evaluation considerations
- How does the platform scale across studies, regions, and functions?
- What changes as operational complexity increases?
- How are integrations and upgrades managed without disrupting active trials?
Why this matters
Early architectural choices determine whether platforms remain manageable as trial portfolios grow. Complexity that is hidden at small scale tends to surface during inspections, audits, or portfolio expansion.
Questions to ask clinical trial platform vendors
Vendor discussions should clarify architectural decisions, data governance, and compliance controls — not only functional capabilities.
How many databases support the platform, and how are they governed?
Where do authoritative records for subjects, sites, and documents reside?
How is validation maintained as the platform is configured or updated?
How are audit trails preserved during migrations, upgrades, or integrations?
How would inspection preparation be handled without cross-system reconciliation?
Architecture-level answers are often more informative than feature lists during vendor evaluation. Over-reliance on manual processes or procedural workarounds may indicate structural limitations that emerge as trial operations scale.
Using the clinical trial platform evaluation checklist
This checklist is most effective when used alongside:
Apply alongside
- Functional requirements
- User workflows
- Operational objectives
- Compliance expectations
Useful during
- Early vendor shortlisting
- System architecture reviews
- Proof-of-concept evaluations
- Portfolio-level technology assessments
Key takeaway
By grounding evaluation in architectural realities, buyers can reduce uncertainty, avoid hidden operational costs, and make more sustainable platform decisions.